ClinicalTrials.gg
TerminatedNCT05006950Updated Sep 19, 2022

SPY Fluorescence Imaging Systems and Indocyanine Green to Determine the Percentage of Successful Critical Anatomy Recognition in Laparoscopic Cholecystectomy Surgeries.

A Phase 1 interventional study of Stryker1688 Fluorescence imaging system in Cholecystitis, sponsored by Stryker Endoscopy. Terminated at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-09-19.

Sponsored by Stryker Endoscopy (part of Stryker) · Phase 1, Interventional, and Health services research

How we know

Why this study was terminated
Business/strategic reasons and low accrual rate

From the registry’s dates

  • Primary completion was Feb 2022, 4 years 9 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
50
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 28 studies in Cholecystitis with a site in United States — 4 open to participants now, 4 under way, none of them phase 3. Cholecystitis · United States.

Enrollment
9th of 21
50 · median 30
Started
2021
with 2 others
Phase 1
Only one
of the 28
Registered
23rd of 28
by date

Among the 28 studies in Cholecystitis with a site in United States, this one is the 9th largest by enrollment of the 21 interventional ones that give a count, is one of 3 that started in 2021, is the only one in phase 1, and was the 23rd registered.

Cholecystitis

193 studies on the registry are indexed under Cholecystitis; 36 are open to participants now.

Browse Cholecystitis studies →

Open to participants now

4 of the 28 studies in Cholecystitis with a site in United States are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 23 Cholecystitis studies recruiting now, 14 (61%) set no upper age limit and 7 (30%) stop at 75 or younger; 2 take children under 18; 5 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies in Cholecystitis with a site in United States, or all of them as a file.
02

Study summary

This is a prospective single arm, single center study estimating percentage of successful critical anatomy recognition in laparoscopic cholecystectomy surgeries using SPY fluorescence imaging and ICG, with each surgery also providing a white light 360 degree images.

The primary objective is to determine the percentage of successful critical anatomy recognition using intra-operative SPY fluorescence imaging and ICG: and to describe complications associated with intra-operative decision making in patients undergoing laparoscopic cholecystectomy.

03

Conditions studied

  • Cholecystitis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject is 18 years of age or older
  • Subject is scheduled to undergo laparoscopic cholecystectomy, elective or emergent
  • Subject provides and signs an approved informed consent document for the study
  • Subject is willing to comply with the protocol and study visit schedule

Exclusion criteria

Exclusion Criteria:

  • Subject is pregnant or lactating
  • Subject has a known allergy or history of adverse reaction to ICG, iodine or iodine dyes
  • Subject has known history of cholangitis, pancreatitis, prior bile duct injury, coagulopathy or known pre-existing liver disease
  • Subjects who, in the Investigator's opinion, have any medical condition that may make the subject a poor candidate for the investigation, interferes with the interpretation of study results, or integrity of the study
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 1
Primary purpose
Health services research
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (actual)

Interventions

  • DeviceStryker1688 Fluorescence imaging system

    The purpose of this study is to use SPY fluorescence imaging systems and indocyanine green (ICG) as a tool to determine the percentage of successful critical anatomy recognition and to describe complications associated with intra-operative decision making in patients undergoing laparoscopic cholecystectomy.

06

What researchers measure

Primary outcomes

  1. Outcome 1

    To determine the percentage of successful critical anatomy recognition using intra-operative SPY fluorescence imaging and ICG in subjects undergoing laparoscopic cholecystectomy

    Time frame: Intra-op visit

Secondary outcomes

  1. Outcome 2

    To estimate the number of times a surgeon altered the surgical plan due to information identified/revealed by SPY fluorescence imaging

    Time frame: Intra-op visit

Other outcomes

  1. Outcome 3

    To estimate the number of post-operative complications (related to gall bladder surgery

    Time frame: Post op follow- up (7-14 days)

07

Study locations

1 site
  • Anne Arundel Medical Center
    Annapolis, Maryland 21401, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2021 to primary completion in Feb 2022, 7 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 9, 2021
First posted
Aug 16, 2021
StartActual
Jun 28, 2021
Primary completionActual
Feb 8, 2022
CompletionActual
Sep 7, 2022
Last update
Sep 19, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 19, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05006950
Lead sponsor
Stryker Endoscopy
Responsible party
Sponsor
First posted
Aug 16, 2021
Start date
Jun 28, 2021
Primary completion
Feb 8, 2022
Completion
Sep 7, 2022
Last update
Sep 19, 2022

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion